User: Guest  Login
Document type:
journal article 
Author(s):
Boeck, S; Hoehler, T; Seipelt, G; Mahlberg, R; Wein, A; Hochhaus, A; Boeck, HP; Schmid, B; Kettner, E; Stauch, M; Lordick, F; Ko, Y; Geissler, M; Schoppmeyer, K; Kojouharoff, G; Golf, A; Neugebauer, S; Heinemann, V 
Title:
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. 
Abstract:
BACKGROUND: To compare the efficacy and safety of three different chemotherapy doublets in the treatment of advanced pancreatic cancer (PC). PATIENTS AND METHODS: At total of 190 patients were randomly assigned to receive capecitabine 1000 mg/m(2) twice daily on days 1-14 plus oxaliplatin 130 mg/m(2) on day 1 (CapOx), capecitabine 825 mg/m(2) twice daily on days 1-14 plus gemcitabine 1000 mg/m(2) on days 1 and 8 (CapGem) or gemcitabine 1000 mg/m(2) on days 1 and 8 plus oxaliplatin 130 mg/m(2) on...    »
 
Journal title abbreviation:
Ann Oncol 
Year:
2008 
Journal volume:
19 
Journal issue:
Pages contribution:
340-7 
Language:
eng 
Print-ISSN:
0923-7534 
TUM Institution:
III. Medizinische Klinik und Poliklinik